GB0902916D0 - Antibody therapy - Google Patents

Antibody therapy

Info

Publication number
GB0902916D0
GB0902916D0 GBGB0902916.6A GB0902916A GB0902916D0 GB 0902916 D0 GB0902916 D0 GB 0902916D0 GB 0902916 A GB0902916 A GB 0902916A GB 0902916 D0 GB0902916 D0 GB 0902916D0
Authority
GB
United Kingdom
Prior art keywords
antibody therapy
antibody
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0902916.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Antibodies Ltd
Original Assignee
Fusion Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Antibodies Ltd filed Critical Fusion Antibodies Ltd
Priority to GBGB0902916.6A priority Critical patent/GB0902916D0/en
Publication of GB0902916D0 publication Critical patent/GB0902916D0/en
Priority to PCT/GB2010/050304 priority patent/WO2010094981A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
GBGB0902916.6A 2009-02-20 2009-02-20 Antibody therapy Ceased GB0902916D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0902916.6A GB0902916D0 (en) 2009-02-20 2009-02-20 Antibody therapy
PCT/GB2010/050304 WO2010094981A2 (en) 2009-02-20 2010-02-22 Antibody therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0902916.6A GB0902916D0 (en) 2009-02-20 2009-02-20 Antibody therapy

Publications (1)

Publication Number Publication Date
GB0902916D0 true GB0902916D0 (en) 2009-04-08

Family

ID=40565474

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0902916.6A Ceased GB0902916D0 (en) 2009-02-20 2009-02-20 Antibody therapy

Country Status (2)

Country Link
GB (1) GB0902916D0 (en)
WO (1) WO2010094981A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853719A1 (en) * 2011-10-27 2013-05-02 Nkt Therapeutics Inc. Humanized antibodies to inkt
CN114989297B (en) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 Kit comprising horseradish peroxidase-labeled antibody

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP2316859A1 (en) 2005-04-09 2011-05-04 Fusion Antibodies Limited Cathepsin S antibody
GB0620255D0 (en) 2006-10-12 2006-11-22 Fusion Antibodies Ltd Antibody and uses thereof

Also Published As

Publication number Publication date
WO2010094981A2 (en) 2010-08-26
WO2010094981A3 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
HRP20180952T1 (en) Anti-dll3 antibody
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
ZA201104545B (en) Anti-siglec-15 antibody
GB0909906D0 (en) Antibodies
HUE040213T2 (en) Anti-tim-3 antibody
PL2616489T3 (en) Anti-hutnfr1 antibody
EP2427496A4 (en) Anti-vegf-d antibodies
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
GB0815788D0 (en) Therapeutic antibodies
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) Anti-c-mpl antibodies
EP2324059A4 (en) Anti-pamp therapeutic antibodies
EP2424892A4 (en) Dc-stamp antibodies
GB0916997D0 (en) Combination therapy
GB0902916D0 (en) Antibody therapy
GB0907973D0 (en) Combination therapy
GB201007957D0 (en) Antibody
GB0921244D0 (en) Therapy
GB0914820D0 (en) WATerian therapy
GB0903321D0 (en) Therapy
GB0903319D0 (en) Therapy
GB0911712D0 (en) Antibody
GB0908945D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)